Fig. 2From: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort studyPatient attrition. FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol, COPD chronic obstructive pulmonary disease, HES Hospital Episode Statistics, SITT single-inhaler triple therapy, BDP/FOR/GLY beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromideBack to article page